{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:50:19Z","timestamp":1790869819339,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6095,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1093\/annonc\/mdg201","type":"journal-article","created":{"date-parts":[[2003,4,17]],"date-time":"2003-04-17T22:48:43Z","timestamp":1050619723000},"page":"758-765","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as \u2018in vivo purge\u2019 and consolidative immunotherapy following autologous stem cell transplantation"],"prefix":"10.1016","volume":"14","author":[{"given":"J.","family":"Mangel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pavlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Berinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg201_bb0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0015","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0020","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0025","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0030","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0035","first-page":"1927","article-title":"Rituximab for the treatment of relapsing refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdg201_bb0045","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle-cell lymphoma","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdg201_bb0055","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0065","first-page":"92a","article-title":"Excellent tolerance of rituximab when given after mitoxantronecyclophosphamide an effective and safe combination for indolent NHL","volume":"94","author":"Emmanouilides","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdg201_bb0075","first-page":"115","article-title":"Stem cell function and engraftment is not affected by \u2018in vivo purging\u2019 with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin\u2019s lymphoma","volume":"26","author":"Buckstein","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0085","first-page":"351b","article-title":"Mobilization of peripheral stem cells in patients with indolent lymphoma using a combination of MINE with rituximab","volume":"94","author":"Emmanouilides","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0090","first-page":"638a","article-title":"In vivo purging with rituximab during stem cell transplantation for indolent lymphoma","volume":"94","author":"Flinn","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","article-title":"In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin\u2019s lymphoma","volume":"109","author":"Voso","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdg201_bb0100","first-page":"482a","article-title":"Treatment of follicular and mantle cell non-Hodgkin\u2019s lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem cell transplantation","volume":"96","author":"Brugger","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0105","first-page":"862a","article-title":"Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin\u2019s lymphomas","volume":"98","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0110","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0115","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0125","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0130","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demiden","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1093\/annonc\/mdg201_bb0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","article-title":"Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study","volume":"22","author":"Iacona","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdg201_bb0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","article-title":"Multiple roles for the major histocompatibility complex class I-related receptor FcRN","volume":"18","author":"Ghetie","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1093\/annonc\/mdg201_bb0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Carton","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdg201_bb0155","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg201_bb0160","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963509X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341963509X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/5\/758\/567856\/mdg201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:04:19Z","timestamp":1582250659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341963509X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S092375341963509X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg201","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}